| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2004 | CA2109796C Modulation of cellular response to external stimuli |
| 04/27/2004 | CA2104214C Cytokine inhibitors |
| 04/27/2004 | CA2103708C Treatment of ovarian cancer |
| 04/23/2004 | CA2445817A1 Novel derivatives of imidazoline, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2004 | WO2004034023A2 Methods of synthesizing 3-amino-1,2,4-benzotriazines |
| 04/22/2004 | WO2004033725A2 Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene |
| 04/22/2004 | WO2004033663A2 Carbohydrate-based synthetic vaccines for hiv |
| 04/22/2004 | WO2004033620A2 Methods and compositions for therapeutic use of rna interference |
| 04/22/2004 | WO2004033502A1 Chitosan-containing polysaccharide, process for producing the same and use thereof |
| 04/22/2004 | WO2004033496A1 Agonists and antagonists of the human odorant receptor or17-4 and uses thereof |
| 04/22/2004 | WO2004033484A2 Use of stable glutamine derivatives to improve drug absorption |
| 04/22/2004 | WO2004033478A2 Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory |
| 04/22/2004 | WO2004033475A1 Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same |
| 04/22/2004 | WO2004033473A1 Glucose-based compounds with affinity to p-selectin |
| 04/22/2004 | WO2004033465A1 2' oxo-voruscharin and derivatives thereof |
| 04/22/2004 | WO2004033463A1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES |
| 04/22/2004 | WO2004033454A1 Therapeutic compounds based on pyrazolopyridine derivatives |
| 04/22/2004 | WO2004033446A1 Protein tyrosine kinase inhibitors |
| 04/22/2004 | WO2004033443A1 Halogen substituted hexahydroxy biphenyl derivatives, their preparation and their uses as medicament |
| 04/22/2004 | WO2004033440A1 Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
| 04/22/2004 | WO2004033439A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 04/22/2004 | WO2004033436A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
| 04/22/2004 | WO2004033427A1 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
| 04/22/2004 | WO2004033425A1 Pyrrolidine derivatives for use in treating heaptitis c virus infection |
| 04/22/2004 | WO2004033423A2 Anticancer compounds |
| 04/22/2004 | WO2004033420A1 2,2-DI-SUBSTITUTED 1α,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE |
| 04/22/2004 | WO2004033417A2 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 04/22/2004 | WO2004033414A1 Mu opioid receptor ligands: methods of use and synthesis |
| 04/22/2004 | WO2004033412A1 Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments |
| 04/22/2004 | WO2004033042A1 Treatment of amm |
| 04/22/2004 | WO2004032972A1 An oral formulation of methylglyoxal and its imino acid conjugates for human use |
| 04/22/2004 | WO2004032969A1 Modulation of immune function |
| 04/22/2004 | WO2004032968A1 Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity |
| 04/22/2004 | WO2004032966A1 Cell growth regulator |
| 04/22/2004 | WO2004032965A1 Endogenous repair factor production promoters |
| 04/22/2004 | WO2004032964A1 Remedies for allergic diseases |
| 04/22/2004 | WO2004032952A1 Use of ghrelin for treating malnutrition in gastrectomized individuals |
| 04/22/2004 | WO2004032950A1 Method and composition for reducing cravings for a craved substance |
| 04/22/2004 | WO2004032945A1 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations |
| 04/22/2004 | WO2004032944A1 Composition for treating hemorrhoids |
| 04/22/2004 | WO2004032943A1 Combination preparation of hyaluronic acid and at least one local anesthetic and the use thereof |
| 04/22/2004 | WO2004032942A1 Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| 04/22/2004 | WO2004032941A1 Pharmaceutical compositions containing polydatin or its salts and their application |
| 04/22/2004 | WO2004032940A1 Classes of compounds that interact with gpcrs |
| 04/22/2004 | WO2004032939A1 Combination therapy with gemcitabine and zd6126 |
| 04/22/2004 | WO2004032938A1 Use of dihydroimidazolones for the treatment of epilepsy in dogs |
| 04/22/2004 | WO2004032937A1 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 04/22/2004 | WO2004032935A1 Treatment of aml |
| 04/22/2004 | WO2004032934A1 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
| 04/22/2004 | WO2004032933A1 Method for treatment of cancer |
| 04/22/2004 | WO2004032932A1 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 04/22/2004 | WO2004032931A1 Method for treatment of cancer |
| 04/22/2004 | WO2004032930A1 Method of treatment for cancer |
| 04/22/2004 | WO2004032929A2 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease |
| 04/22/2004 | WO2004032927A1 Transdermal preparations comprising eperisone, tolperisone or salts thereof |
| 04/22/2004 | WO2004032926A1 Gelled laxative compositions |
| 04/22/2004 | WO2004032925A1 Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents |
| 04/22/2004 | WO2004032924A1 The use of berberine as insulin sensitizer |
| 04/22/2004 | WO2004032923A1 Epothilone derivatives for the treatment of multiple myeloma |
| 04/22/2004 | WO2004032922A1 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist |
| 04/22/2004 | WO2004032920A1 Stabilized pharmaceutical preparation comprising an amorphous active substance |
| 04/22/2004 | WO2004032919A1 Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility |
| 04/22/2004 | WO2004032918A1 Treatment of inflammatory conditions with ∝-3 polyunsaturated fatty acids |
| 04/22/2004 | WO2004032917A1 Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
| 04/22/2004 | WO2004032916A1 A composition comprising selegeline, procaine, vinpocetine, trimethylglycinean and a n-gaba ingredient for treating neurodegenerative disorders |
| 04/22/2004 | WO2004032915A1 Anti-influenza virus agent |
| 04/22/2004 | WO2004032914A2 Use of a propargyl alcohol enantiomer for the treatment of dermatological disorders |
| 04/22/2004 | WO2004032913A1 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
| 04/22/2004 | WO2004032912A1 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 04/22/2004 | WO2004032911A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/22/2004 | WO2004032910A1 Injectable 2,6-diisopropylphenol-containing anesthetic composition and methods |
| 04/22/2004 | WO2004032909A2 Stabilized pharmaceutical composition containing basic excipients |
| 04/22/2004 | WO2004032908A2 Method of inhibiting angiogenesis |
| 04/22/2004 | WO2004032906A1 Gastro-retentive levodopa delivery form |
| 04/22/2004 | WO2004032905A1 Gabapentin tablets and methods for their preparation |
| 04/22/2004 | WO2004032904A1 Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
| 04/22/2004 | WO2004032903A2 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier |
| 04/22/2004 | WO2004032902A1 Solid particulate antifungal compositions for pharmaceutical use |
| 04/22/2004 | WO2004032900A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | WO2004032899A1 Antibiotic formulation for intramammary administration in milking animals |
| 04/22/2004 | WO2004032882A2 Chemical compounds |
| 04/22/2004 | WO2004032877A2 Compositions, organisms and methodologies employing a novel human kinase |
| 04/22/2004 | WO2004032876A2 Deguelin as a chemopreventive agent for lung cancer |
| 04/22/2004 | WO2004032874A2 AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
| 04/22/2004 | WO2004032873A2 Therapeutic combination of carnitine and antioxidant polyphenols |
| 04/22/2004 | WO2004032872A2 Epo D + 5-FU/GEMCITABINE |
| 04/22/2004 | WO2004032869A2 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid |
| 04/22/2004 | WO2004032866A2 Therapeutic formulations |
| 04/22/2004 | WO2004032864A2 X-nitro compounds, pharmaceutical compositions thereof and uses therof |
| 04/22/2004 | WO2004032861A2 Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
| 04/22/2004 | WO2004032858A2 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 04/22/2004 | WO2004032854A2 Pharmaceutical compositions for treatment of parkinson's disease |
| 04/22/2004 | WO2004032853A2 Compositions and methods for treating sexual dysfunction |
| 04/22/2004 | WO2004032849A2 Methods of administering fgf18 |
| 04/22/2004 | WO2004032848A2 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 04/22/2004 | WO2004032844A2 Compositions and methods for treating pain |
| 04/22/2004 | WO2004032843A2 Mucoadhesive tetracycline formulations |
| 04/22/2004 | WO2004032840A2 Compounds, compositions, and methods |
| 04/22/2004 | WO2004032827A2 Hepatitis c virus inhibitors |
| 04/22/2004 | WO2004032826A2 Process for preparing tannate tablet capsule or other solid dosage forms |